Document is current
Any future updates will be listed below
-
Authors
Thomsen, Liv Cecilie Vestrheim https://orcid.org/0000-0002-6787-8518
Honoré, Alfred https://orcid.org/0000-0003-0420-2585
Reisæter, Lars Anders Rokne https://orcid.org/0000-0002-1242-1502
Almås, Bjarte https://orcid.org/0000-0003-4484-040X
Børretzen, Astrid
Helle, Svein Inge
Førde, Kristina
Kristoffersen, Einar Klæboe https://orcid.org/0000-0002-4928-4417
Kaada, Silje Helland
Melve, Guro Kristin
Haslerud, Torjan Magne
Biermann, Martin https://orcid.org/0000-0002-5550-1035
Bigalke, Iris
Kvalheim, Gunnar
Azeem, Waqas https://orcid.org/0000-0001-7334-2464
Olsen, Jan Roger https://orcid.org/0000-0001-6547-431X
Gabriel, Benjamin https://orcid.org/0000-0003-0762-9082
Knappskog, Stian https://orcid.org/0000-0002-4153-1655
Halvorsen, Ole Johan
Akslen, Lars Andreas https://orcid.org/0000-0003-2710-9543
Bahn, Duke
Pantel, Klaus https://orcid.org/0000-0001-5736-2772
Riethdorf, Sabine https://orcid.org/0000-0003-0028-5643
Ragde, Haakon
Gjertsen, Bjørn Tore https://orcid.org/0000-0001-9358-9704
Øyan, Anne Margrete
Kalland, Karl-Henning https://orcid.org/0000-0003-4486-2334
Beisland, Christian https://orcid.org/0000-0002-3216-4937
-
Funding
Funding for this research was provided by:
Research Council of Norway, Norway (223250, 287829, 223250, 287829, 223250, 287829, 223250, 287829)
Helse Vest, Norway (912062, 911626, 911747, 911582, 911778, 912226, and 980058, 912062, 911626, 911747, 911582, 911778, 912226, and 980058, 912062, 911626, 911747, 911582, 911778, 912226, and 980058)
Helse Vest Strategic grants of Personalized Therapy (303484)
Norwegian Cancer Society, Norway (204947, 204947)
Bergen Research Foundation/Trond Mohn Stiftelse, Norway
Bergen Stem Cell Consortium, Norway (502027, 502027)
University of Bergen
- License Information
-
More Information
Article History
Received: 12 March 2022
Accepted: 3 March 2023
First Online: 20 March 2023
Declarations
:
: Dr. Gjertsen reports other from Kinn Therapeutics AS, other from Alden Cancer Therapeutics 2 AS, personal fees from BerGenBio AS, personal fees from Novartis AS, personal fees from Seattle Genetics Inc., personal fees from Pfizer, non-financial support from Roche, non-financial support from MSD, outside the submitted work. Dr. Kalland reports grants from Research Council of Norway, grants from The Norwegian Cancer Society, during the conduct of the study; In addition, Dr. Kalland has a patent PCT/EP2017/077698 pending and is the CEO of and owns Stocks in the Company Alden Cancer Therapy II AS that has sponsored the trial registered at ClinicalTrials.gov Identifier: NCT02423928 and which is published in the presently submitted manuscript. He has received no salary or remuneration from Alden Cancer Therapy II AS. Dr. Øyan owns stocks in the Company Alden Cancer Therapy II AS that has sponsored the trial registered at ClinicalTrials.gov Identifier: NCT02423928 and which is published in the presently submitted manuscript. She has received no salary or remuneration from Alden Cancer Therapy II AS. Dr. Gabriel reports grants from Norwegian Cancer Society during the conduct of the study. Dr Thomsen reports personal fees from Bayer and AstraZeneca, sitting on the advisory board for Eisai Co., and financial support from AstraZeneca to a researcher-initiated trial. Dr Beisland reports personal fees from Pfizer, sitting on advisory boards for BMS and MSD, and having travel expenses covered by Olympus. The remaining authors have no conflicts of interest to report.
: The protocol was approved by the National Regional Ethics Committee (REK 2014/1052) with amendments during 2015–2019, as well as the Norwegian Medicines Agency. The trial is registered in ClinicalTrials.gov (NCT02423928).
: Written informed consent was obtained from all patients.
: Not applicable.
